Cara Therapeutics has granted licensing worldwide rights with the exception of the US, Japan and South Korea to commercialize its Korsuva (CR845/difelikefalin) injection to Vifor Fresenius Medical Care Renal Pharma (VFMCRP).
Alivio Therapeutics, an affiliate of PureTech Health, announced that the US Patent and Trademark Office (USPTO) issued U.S. Patent Nos. 9,962,339 and 9,974,859, related to its inflammation-targeting technology platform.
Roche's Hemlibra (emicizumab) has significantly reduced bleeding in hemophilia patients, which was demonstrated in two phase 3 Haven studies.
OptiBiotix Health has entered into a five year agreement with Akums Drugs and Pharmaceuticals to exclusively manufacture and supply products featuring OptiBiotix's cholesterol and blood pressure reducing strain LPLDL in India.
Surface Pharmaceuticals, an affiliated company of Imprimis Pharmaceuticals, has entered into a definitive stock purchase agreement with an affiliate of Flying L Partners to raise proceeds of about $20m in a private placement of its Series A preferred stock.
Zymeworks and Daiichi Sankyo have entered into a new license agreement, building upon their cross-licensing and collaboration agreement signed in 2016.
Eli Lilly and Company (Lilly) has agreed to acquire Canadian cancer drug developer AurKa Pharma from TVM Capital Life Science in a deal worth $575m.
Eli Lilly and Company (Lilly) has agreed to acquire Armo BioSciences, a US-based late-stage immuno-oncology company, for about $1.6bn in an all-cash deal.
Escient Pharmaceuticals has been launched with $40m Series A financing to advance G protein-coupled receptor (GPCR)-targeted drugs to address serious, unserved medical needs.
Forma Therapeutics and the University of Oxford have entered into a collaboration and license agreement to identify, validate and develop deubiquitinating enzyme (DUB) inhibitors for the treatment of neurodegenerative diseases.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.